Vanda Pharmaceuticals Inc. (VNDA) Increases Again; Strong Momentum for Buyers

February 15, 2018 - By Ivan Hodges

Investors sentiment increased to 1.43 in 2017 Q3. Its up 0.26, from 1.17 in 2017Q2. It improved, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported.
69,942 were reported by First Lp. Orbimed Lc invested in 0.17% or 967,859 shares. Hbk Investments Limited Partnership stated it has 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). 988,270 were reported by Venbio Select Advisor Ltd Llc. Northern Tru has 591,786 shares. Palo Alto Invsts Ltd Co reported 4.16M shares. Hong Kong-based Point72 Asia (Hong Kong) has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). 10,967 are owned by Massachusetts Financial Ma. 114,363 were reported by Alliancebernstein Lp. North Star Investment Mngmt reported 0.01% stake. Morgan Stanley accumulated 1.08 million shares or 0.01% of the stock. Barclays Public Ltd Llc has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). National Bank & Trust Of Montreal Can invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Alabama-based Kistler has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). State Board Of Administration Of Florida Retirement Sys invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Since January 2, 2018, it had 0 insider buys, and 4 selling transactions for $3.36 million activity. 191,760 shares were sold by Polymeropoulos Mihael Hristos, worth $2.93 million on Tuesday, January 2. 8,568 shares valued at $130,777 were sold by Birznieks Gunther on Tuesday, January 2. Gulino Richard L. sold $157,565 worth of stock.

The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! The stock increased 5.99% or $0.95 during the last trading session, reaching $16.8. About 314,252 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since February 15, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.
The move comes after 5 months positive chart setup for the $754.78M company. It was reported on Feb, 15 by Barchart.com. We have $17.30 PT which if reached, will make NASDAQ:VNDA worth $22.64 million more.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on February, 21. They expect $-0.12 EPS, down 400.00 % or $0.16 from last year’s $0.04 per share. After $-0.10 actual EPS reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 22 analyst reports since September 2, 2015 according to SRatingsIntel. On Monday, June 26 the stock rating was maintained by Jefferies with “Buy”. On Sunday, November 12 the stock rating was maintained by Oppenheimer with “Buy”. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The firm has “Market Outperform” rating given on Friday, August 26 by JMP Securities. Piper Jaffray initiated the shares of VNDA in report on Tuesday, June 27 with “Buy” rating. The rating was maintained by Oppenheimer on Thursday, August 3 with “Buy”. As per Thursday, August 3, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by Oppenheimer given on Monday, January 8. Piper Jaffray maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Thursday, October 19 with “Buy” rating. As per Monday, October 30, the company rating was maintained by Oppenheimer.

More recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Marketwatch.com which released: “Vanda Pharma shares decline as goal of itch drug study not reached” on September 13, 2017. Also Prnewswire.com published the news titled: “Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial …” on February 14, 2018. Seekingalpha.com‘s news article titled: “Vanda Pharmaceuticals’ (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results …” with publication date: November 08, 2017 was also an interesting one.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $754.78 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.